RxDoctor Payments Data

Juan Miranda Iglesias, MD

Cardiovascular Disease · Guayama, PRNPI 1356419469

Payments from drug & device makers

$1,422in general payments, 2019–2025

Across 50 payments — averaging $28.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$496
  • Medtronic$424
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$204
  • Pfizer$125
  • AstraZeneca$84
  • Boehringer Ingelheim$23
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$1,422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson15$496
Medtronic3$424
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)20$204
Pfizer1$125
AstraZeneca5$84
Boehringer Ingelheim1$23
PBG Puerto Rico LLC2$20
E.r. Squibb & Sons, L.L.C.1$19
Amgen1$19
Pfizer Pharmaceuticals LLC1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,422 in reported general payments places this provider in the 35th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$13,154
Medicare patients
28
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$53,854
FarxigaDapagliflozin Propanediol76$48,491
XareltoRivaroxaban65$48,370
EliquisApixaban68$44,889
EntrestoSacubitril/Valsartan48$40,903
Repatha SureclickEvolocumab30$16,828
JanumetSitagliptin Phos/Metformin Hcl11$10,993
Trijardy XrEmpaglifloz/Linaglip/Metformin13$10,436
Metoprolol Succinate189$3,324
Diltiazem 12hr ErDiltiazem Hcl14$3,247
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide95$3,172
Rosuvastatin Calcium181$2,544
Valsartan82$2,449
Atorvastatin Calcium177$2,283
Losartan Potassium153$1,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr$23$64,29079 claims
AstraZenecaFarxiga$84$48,49176 claims
Johnson & JohnsonXarelto$496$48,37065 claims
PfizerEliquis$125$44,88968 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Guayama

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →